Solventum Corporation (SOLV) Return on Equity (ROE): 28.82%
Is Solventum Corporation’s return on equity (ROE) high or low?
Solventum Corporation's return on equity (ROE) of 28.82% is 111% above its 5-year average of 13.68%, near the high end of its 5-year range (0.00%–30.82%).
As of Friday, June 12, 2026. 22.61% above its 12-month average of 23.51%.
SOLV Return on Equity (ROE) Chart
SOLV Average Return on Equity (ROE) Chart
SOLV Current vs Average Return on Equity (ROE) Chart
SOLV Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
28.82%
RETURN ON EQUITY (ROE) AVG TTM
23.51%
RETURN ON EQUITY (ROE) AVG 3Y
17.50%
RETURN ON EQUITY (ROE) AVG 5Y
13.68%
RETURN ON EQUITY (ROE) AVG 10Y
13.68%
RETURN ON EQUITY (ROE) AVG 15Y
13.68%
RETURN ON EQUITY (ROE) AVG 20Y
13.68%
CURRENT VS TTM AVG
+22.61%
CURRENT VS 3Y AVG
+64.71%
CURRENT VS 5Y AVG
+110.62%
CURRENT VS 10Y AVG
+110.62%
CURRENT VS 15Y AVG
+110.62%
CURRENT VS 20Y AVG
+110.62%
SOLV Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.72B | 28.82% | 23.51% | 17.50% | 13.68% |
| Align Technology, Inc. (ALGN) | $12.64B | 10.36% | 10.54% | 10.84% | 19.93% |
| Baxter International Inc. (BAX) | $10.58B | -18.17% | -12.46% | -8.76% | -1.37% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -6.28% | -2.13% | 6.32% | 9.65% |
| Tempus AI, Inc. (TEM) | $8.65B | -72.74% | -651.33% | -315.37% | -198.08% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 2.46% | -8.94% | -15.72% | 1.14% |
| Moderna, Inc. (MRNA) | $19.70B | -43.12% | -32.64% | -13.90% | 0.25% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | -2.97% | 25.09% | 5.57% | 0.40% |
| BioNTech SE (BNTX) | $22.39B | -6.79% | -4.55% | 10.63% | 21.70% |
Return Analysis
ROE
28.8%
ROA
10.2%
Solventum Corporation Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Solventum Corporation Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Solventum Corporation (SOLV)?
- The return on equity (ROE) for SOLV stock is 28.82%.
- Is Solventum Corporation's return on equity (ROE) high or low?
- Solventum Corporation's return on equity (ROE) of 28.82% is 111% above its 5-year average of 13.68%, near the high end of its 5-year range (0.00%–30.82%).
- What is the TTM average return on equity (ROE) for Solventum Corporation (SOLV)?
- The TTM average return on equity (ROE) for SOLV stock is 23.51%.
- What is the 3Y average return on equity (ROE) for Solventum Corporation (SOLV)?
- The 3Y average return on equity (ROE) for SOLV stock is 17.50%.
- What is the 5Y average return on equity (ROE) for Solventum Corporation (SOLV)?
- The 5Y average return on equity (ROE) for SOLV stock is 13.68%.
- What is the 10Y average return on equity (ROE) for Solventum Corporation (SOLV)?
- The 10Y average return on equity (ROE) for SOLV stock is 13.68%.
- What is the 15Y average return on equity (ROE) for Solventum Corporation (SOLV)?
- The 15Y average return on equity (ROE) for SOLV stock is 13.68%.
- What is the 20Y average return on equity (ROE) for Solventum Corporation (SOLV)?
- The 20Y average return on equity (ROE) for SOLV stock is 13.68%.
Solventum Corporation Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.82% |
| 2024-12-31 | 16.19% |
| 2023-12-31 | 11.54% |
| 2022-12-31 | 11.44% |
| 2021-12-31 | 12.11% |
| 2020-12-31 | 0.00% |
Related Metrics
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson